These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25888191)

  • 1. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
    Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
    Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
    Casari G; Dall'Ora M; Melandri A; Masciale V; Chiavelli C; Prapa M; Neri G; Spano MC; Murgia A; D'Esposito A; Baschieri MC; Ceccherelli GB; Dominici M; Grisendi G
    Cytotherapy; 2023 Jun; 25(6):605-614. PubMed ID: 37012089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
    Grisendi G; Bussolari R; Cafarelli L; Petak I; Rasini V; Veronesi E; De Santis G; Spano C; Tagliazzucchi M; Barti-Juhasz H; Scarabelli L; Bambi F; Frassoldati A; Rossi G; Casali C; Morandi U; Horwitz EM; Paolucci P; Conte P; Dominici M
    Cancer Res; 2010 May; 70(9):3718-29. PubMed ID: 20388793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production.
    Lee HJ; Yang HM; Choi YS; Park SH; Moon SH; Lee YS; Sung YC; Kim SJ
    Ann Surg; 2013 May; 257(5):952-60. PubMed ID: 23108118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy.
    Yuan Z; Lourenco Sda S; Sage EK; Kolluri KK; Lowdell MW; Janes SM
    Cytotherapy; 2016 Jul; 18(7):860-9. PubMed ID: 27260207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
    Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
    Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
    Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
    Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
    Luetzkendorf J; Mueller LP; Mueller T; Caysa H; Nerger K; Schmoll HJ
    J Cell Mol Med; 2010 Sep; 14(9):2292-304. PubMed ID: 19508388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.
    Lathrop MJ; Sage EK; Macura SL; Brooks EM; Cruz F; Bonenfant NR; Sokocevic D; MacPherson MB; Beuschel SL; Dunaway CW; Shukla A; Janes SM; Steele C; Mossman BT; Weiss DJ
    Cancer Gene Ther; 2015 Jan; 22(1):44-54. PubMed ID: 25525034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models.
    Guiho R; Biteau K; Grisendi G; Chatelais M; Brion R; Taurelle J; Renault S; Heymann D; Dominici M; Redini F
    Cytotherapy; 2018 Aug; 20(8):1037-1045. PubMed ID: 30093324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
    Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
    Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models.
    Guiho R; Biteau K; Grisendi G; Taurelle J; Chatelais M; Gantier M; Heymann D; Dominici M; Redini F
    Int J Cancer; 2016 Dec; 139(12):2802-2811. PubMed ID: 27558972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
    Secchiero P; Melloni E; Corallini F; Beltrami AP; Alviano F; Milani D; D'Aurizio F; di Iasio MG; Cesselli D; Bagnara GP; Zauli G
    Stem Cells; 2008 Nov; 26(11):2955-63. PubMed ID: 18772312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
    Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Tumor Necrosis Factor-Producing Mesenchymal Stem Cells on Apoptosis of Chronic B-lymphocytic Tumor Cells Resistant to Fludarabine-based Chemotherapy.
    Valizadeh A; Ahmadzadeh A; Saki G; Khodadadi A; Teimoori A
    Asian Pac J Cancer Prev; 2015; 16(18):8533-9. PubMed ID: 26745113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.
    Reagan MR; Seib FP; McMillin DW; Sage EK; Mitsiades CS; Janes SM; Ghobrial IM; Kaplan DL
    J Breast Cancer; 2012 Sep; 15(3):273-82. PubMed ID: 23091539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
    Ciavarella S; Grisendi G; Dominici M; Tucci M; Brunetti O; Dammacco F; Silvestris F
    Br J Haematol; 2012 Jun; 157(5):586-98. PubMed ID: 22420897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.
    Mohr A; Lyons M; Deedigan L; Harte T; Shaw G; Howard L; Barry F; O'Brien T; Zwacka R
    J Cell Mol Med; 2008 Dec; 12(6B):2628-43. PubMed ID: 18373740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.